Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor

BMC Biology

Volumn 2, Issue , 2004, Pages

  Joyce, Jeffrey N ^a   Woolsey, Cheryl ^a   Ryoo, Han ^a   Borwege, Sabine ^a   Hagner, Diane ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; DOPAMINE 3 RECEPTOR; DOPAMINE TRANSPORTER; PRAMIPEXOLE; SODIUM CHLORIDE; TRITIUM; TYROSINE 3 MONOOXYGENASE; ANTIPARKINSON AGENT; BENZOTHIAZOLE DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROPROTECTIVE AGENT; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CELL COUNT; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INHIBITION KINETICS; INNERVATION; KNOCKOUT MOUSE; LOW DRUG DOSE; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NEWBORN; NONHUMAN; OPTICAL DENSITY; PARKINSON DISEASE; PROTEIN TRANSPORT; QUANTITATIVE ANALYSIS; RECEPTOR DOWN REGULATION; STEREOLOGY; SUBSTANTIA NIGRA; SYNAPTOSOME; TREATMENT OUTCOME; VENTRAL TEGMENTUM; WILD TYPE; ANIMAL; C57BL MOUSE; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECTS; METABOLISM; NERVE CELL; NERVE FIBER; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; CELL COUNT; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE FIBERS; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RECEPTORS, DOPAMINE D3; THIAZOLES;

EID: 13844281345     PISSN: 17417007     EISSN: None     Source Type: Journal    
DOI: 10.1186/1741-7007-2-22     Document Type: Article

References (51)

1. Grünblatt E, Mandel S, Berkuzki T, Youdim MB: Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov Disord 1999, 14:612-618.
2. Muralikrishnan D, Mohanakumar KP: Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced neurotoxicity in mice. FASEB J 1998, 12:905-912.
3. Kitamura Y, Kohno Y, Nakazawa M, Nomura Y: Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice. Jpn J Pharmacol 1997, 74: 1-57.
4. Gainetdinov RR, Fumagalli F, Jones SR, Caron MG: Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 1997, 69: 322-1325.
5. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ: A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4- phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A 1983, 80:4546-4550.
6. Langston JW, Ballard P, Tetrud JW, Irwin I: Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219:979-980.
7. McNaught KS, Thull U, Carrupt PA, Altomare C, Cellamare S, Carotti A, Testa B, Jenner P, Marsden CD: Nigral cell loss produced by infusion of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 1996, 5:265-274.
8. Cassarino DS, Bennett JP Jr: An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res Brain Res Rev 1999, 29:1-25.
9. Hirsch EC, Hunot S, Hartmann A: Mechanism of cell death in experimental models of Parkinson's disease. Funct Neurol 2000, 15:229-237.
10. Cohen G, Werner P: Free radicals, oxidative stress and neurodegeneration. In Neurodegenerative Disorders Edited by: Calne CB. Philadelphia, PA: WB Saunders; 1994:139-162.
11. Snow BJ, Vingerhoets FJ, Langston JW, Tetrud JW, Sossi V, Calne DB: Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J Neurol Neurosurg Psychiatry 2000, 68:313-316.
12. Marek K, Seibyl J, Shoulson I, Holloway R, Kieburtz K, McDermott M, Kamp C, Shinaman A, Fahn S, Lang A, et al.: Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002, 287: 653-1661.
13. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, et al.: Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003, 54:93-101.
14. Clarke CE, Guttman M: Dopamine agonist monotherapy in Parkinson's disease. Lancet 2002, 360:1767-1769.
15. Stocchi F, Olanow CW: Neuroprotection in Parkinson's disease: clinical trials. Ann Neurol 2003, 53(Suppl 3): 87-S97.
16. 3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J Pharmacol Exp Ther 1995, 275: 99-913.
17. Koeltzow TE, Xu M, Cooper DC, Hu XT, Tonegawa S, Wolf ME, White FJ: Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice. J Neurosci 1998, 18:2231-2238.
18. 2 receptor-deficient mice. Brain Res 1998, 792:253-262.
19. 2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum. J Neurochem 1999, 72:148-156.
20. Zapata A, Witkin JM, Shippenberg TS: Selective D3 receptor agonist effects of (+)-PD 128907 on dialysate dopamine at low doses. Neuropharmacology 2001, 41:351-359.
21. Zou L, Xu J, Jankovic J, He Y, Appel SH, Le W: Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci Lett 2000, 281:167-170.
22. Iida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, Ogawa N: Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 1999, 838:51-59.
23. Lange KW, Rausch WD, Gsell W, Naumann M, Oestreicher E, Riederer P: Neuroprotection by dopamine agonists. J Neural Transm Suppl 1994, 43:183-201.
24. Anderson DW, Neavin T, Smith JA, Schneider JS: Neuroprotective effects of pramipexole in young and aged MPTP-treated mice. Brain Res 2001, 905:44-53.
25. Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S: Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 2001, 56:1559-1564.
26. 2 receptor agonist and anitparkinson agent S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+)and in vivo against 1-methyl- 4-phenyl-1,2,2,6-tetrahydropyridine (MPTP):a comparison to ropinirole. Exp Neurol 2003, 184:393-407.
27. Presgraves S, Ahmed T, Borwege S, Joyce JN: Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. Neurotox Res 2004, 5:579-598.
28. Eshleman AJ, Wolfrum K, Mash DC, Christensen K, Janowsky A: Drug interactions with the dopamine transporter in cryopreserved human caudate. J Pharmacol Exp Ther 2001, 296:442-449.
29. Eshleman AJ, Stewart E, Evenson AK, Mason JN, Blakely RD, Janowsky A, Neve KA: Metabolism of catecholamines by catechol-O-methyltransferase in cells expressing recombinant catecholamine transporters. Journal of Neurochemistry 1997, 69:1459-1466.
30. 3 receptor knockout mice. Pharmacol Biochem Behav 2003, 76: 51-562.
31. Sonsalla PK, Heikkila RE: The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur J Pharmacol 1986, 129:339-345.
32. Hallman H, Lange J, Olson L, Stromberg I, Jonsson G: Neurochemical and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurones in the mouse. J Neurochem 1985, 44:117-127.
33. Ricaurte GA, Langston JW, DeLanney LE, Irwin I, Peroutka SJ, Forno LS: Fate of nigrostriatal neurons in young mature mice given 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment. Brain Res 1986, 376:117-124.
34. Mori S, Fujitake J, Kuno S, Sano Y: Immunohistochemical evaluation of the neurotoxic effects of 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP) on dopaminergic nigrostriatal neurons of young adult mice using dopamine and tyrosine hydroxylase antibodies. Neurosci Lett 1988, 90:57-62.
35. Tatton WG, Greenwood CE: Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 1991, 30:666-672.
36. Seniuk NA, Tatton WG, Greenwood CE: Dose-dependent destruction of the coeruleus-cortical and nigral- striatal projections by MPTP. Brain Res 1990, 527:7-20.
37. Ramirez AD, Wong SK, Menniti FS: Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms. European Journal of Pharmacology 2003, 475: 9-35.
38. Vu TQ, Ling ZD, Ma SY, Robie HC, Tong CW, Chen EY, Lipton JW, Carvey PM: Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine. J Neural Transm 2000, 107:159-176.
39. 3 receptors expressed by all mesencephalic dopamine neurons. J Neurosci 2000, 20:8677-8684.
40. Le Moine C, Bloch B: Rat striatal and mesencephalic neurons contain the long isoform of the D2 dopamine receptor mRNA. Brain Res Mol Brain Res 1991, 10:283-289.
41. 3 receptors. Neuroscience 1999, 91:911-924.
42. 3 receptor ligands modulate extracellular dopamine clearance in the nucleus accumbens. J Neurochem 2002, 81:1035-1042.
43. Thompson TL, Bridges S, Miller C: Modulation of dopamine uptake in rat nucleus accumbens: effect of specific dopamine receptor antagonists and sigma ligands. Neurosci Lett 2001, 312: 69-172.
44. Little KY, Gorebig J, Carroll FI, Mapili J, Meador-Woodruff JH: Lack of dopamine receptor agonists effect on striatal dopamine transporter binding sites. Brain Res 1996, 742:313-316.
45. Kimmel HL, Joyce AR, Carroll FI, Kuhar MJ: Dopamine D1 and D2 receptors influence dopamine transporter synthesis and degradation in the rat. J Pharmacol Exp Ther 2001, 298:129-140.
46. Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, Lamb ME, Leeb-Lundberg LM, Carvelli L, Javitch JA, Galli A: Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci U S A 2000, 97:6850-6855.
47. Chi L, Reith ME: Substrate-induced trafficking of the dopamine transporter in heterologously expressing cells and in rat striatal synaptosomal preparations. J Pharmacol Exp Ther 2003, 307:729-736.
48. Ahlskog JE, Maraganore DM, Uitti RJ, Uhl GR: Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease. JAMA 2002, 288:311-313.
49. Kemmerer ES, Desmond TJ, Albin RL, Kilbourn MR, Frey KA: Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole. Exp Neurol 2003, 183:81-86.
50. Barc S, Page G, Barrier L, Garreau L, Guilloteau D, Fauconneau B, Chalon S: Relevance of different striatal markers in assessment of the MPP+- induced dopaminergic nigrostriatal injury in rat. J Neurochem 2002, 80:365-374.
51. 2 receptor is elevated in the striatum of Parkinson's disease. Mov Disord 1998, 13:788-797.